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A b s t r a c t
Objectives: Ischemic stroke remains one of the top ten causes of death in children. There is evidence for the role 
of pro-inflammatory cytokines, such as IL-6 and the –174G>C promoter polymorphism of the IL-6 gene, in the occur-
rence and outcome of stroke in adults. The aim of the present study was to determine a possible association between
the –174G>C IL-6 polymorphism and occurrence of paediatric stroke, its symptoms and outcome.
Material and methods: The study group consisted of 340 individuals: 80 stroke children, 122 parents of patients and
138 controls. The –174G/C polymorphism was genotyped using the RFLP method. For the analysis of the relationship
between genotypes and stroke we used two alternative methods: the case-control model and the transmission test
for linkage disequilibrium using data from families.
Results: We observed no differences in the transmission of alleles from parents to children. We also did not find any
statistical differences in distribution of genotypes and alleles between patients and controls. However, the analysis showed
that post-stroke epilepsy was genotype-dependent. All children with epilepsy were G allele carriers and none of them
was a CC homozygote whereas about 25% of children without epilepsy had the CC genotype. 
Conclusions: Our study did not show any associations between the IL-6 –174 G>C polymorphism and the occurrence
of stroke but we observed a relation between post-stroke epilepsy and the G allele carrier-state. 
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Introduction 
Stroke in adults is the leading cause of morbidity
and mortality in developing countries. Although child-
hood stroke is not that common it remains one of the
top ten causes of death in children. Children surviv-
ing stroke show a high risk of recurrence and chron-
ic neurological sequels. Multiple risk factors such as
congenital and acquired heart diseases, arteriopathies,
sickle cell anaemia, haematological disorders or infec-
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tions are identified in children with stroke. However,
the aetiology of stroke in many cases remains un known
and seems to be multifactorial [3,17]. The significance
of genetic factors in the aetiology of stroke was con-
firmed by studies of twins, however, genetic and molec-
ular basis of the mechanism underlying paediatric
stroke is still poorly understood [4]. 
There is evidence for the role of pro-inflammato-
ry cytokines, such as interleukin-6 (IL-6), in the occur-
rence and outcome of stroke in adults. IL-6 showed
a significant increase of serum levels already within 
the first hours following the onset of the disease. 
The IL-6 level was significantly correlated with increas-
ing volumes of brain lesion, infarct volume, stroke sever-
ity, and poor functional and neurological outcome
[6,10,18,22,23]. The –174G>C promoter polymorphism
of the IL-6 gene seems to be a functional polymorphism
associated with a different level of secreted protein
according to the genotype. However, different studies
have reported conflicting results. In some populations
of patients [5], higher IL-6 levels are associated with
the GG genotype while in other populations – with the
CC genotype [16]. Some studies in adult patients also
showed an association between the –174G>C IL-6 poly-
morphism and stroke occurrence, an increased risk of
carotid plaque formation, and severity of disability after
the event [7,8,13].
The aim of the present study was to determine
a possible association between the –174G>C IL-6
polymorphism and occurrence of paediatric stroke, its
symptoms and outcome. To avoid some of the prob-
lems often encountered when applying the case-con-
trol design, e.g. the proper control group selection, we
also used an alternative method, the transmission dis-
equilibrium test (TDT) using data from families.
Material and methods
The study group consisted of 340 individuals,
including 80 patients (35 girls and 45 boys), 122 par-
ents of stroke children, and 138 control children. Patients
were recruited from the Department of Neuropae-
diatrics at the Medical University of Silesia in Kato wice
(42 children), the Department of Developmental Neu-
rolo gy at the Medical University of Gdansk (17 pa tients),
the De partment of Paediatric and Adolescent Neuro -
logy at the Jagiellonian University Medical College in
Krakow (12 children) and the Department of Neuro logy
at the Polish Mother’s Memorial Hospital – Research
Institute in Lodz (9 patients). 
The age of patients ranged from 6 months to 18 years
(mean age 8.75 years) at the time of diagnosis, and 
2 to 25 years (mean age 14.33 years) at the time of 
the follow-up.
The control group was age- and sex-matched, and
consisted of children with no history of ischemic stroke
or other vascular diseases. The age of control children
ranged from 3 months up to 18 years (mean age 7.5).
There were 73 boys and 61 girls. The study protocol was
approved by the Ethics Committee of the Medical Uni-
versity of Silesia in Katowice and written consents were
submitted by the patients’ parents.
Genetic analysis
Genomic DNA was extracted from peripheral
leukocytes using the MasterPure™ genomic DNA pu -
rification kit (Epicentre Technologies). The IL-6 –
174G/C polymorphism was genotyped using the res -
triction fragment length polymorphism method
des cribed by Elghannam et al. [9] with own modifi-
cations. The amplification parameters were: initial 1 min
denaturation at 94°C, followed by 35 cycles of 94°C 
for 0.5 min, 64°C for 0.5 min, and 72°C for 0.5 min. The
product of amplification was digested by the Hsp92II
restriction enzyme (Promega) generating fragments:
230 and 75bp for G allele and 121, 109 and 75bp for 
C allele. The fragments were separated on 8% poly-
acrylamide gel and visualized by the AgNO3 staining.
Statistical analysis
The allele frequencies were assessed on the basis
of the genotype distribution. Hardy-Weinberg equi-
librium in all groups was tested by the χ2 test. The trans-
mission/disequilibrium test was used for the analysis
of a possible relationship between the IL-6 –174G/C poly-
morphism and stroke [19]. The test was based on 
the analysis of transmission of specific alleles from 
the heterozygous parents to their affected children.
Transmission of a particular allele to a child is expect-
ed to be 50% if there is no association between the
allele and the disease. An excess transmission to the
offspring is expected if the allele is associated with 
an increased risk of the disease. The frequencies of
transmitted alleles observed in the study were com-
pared with the expected frequencies using the χ2 test.
Alternatively, the case-control method was applied. 
The genotype and allele frequencies were compared
between patients and children without stroke using
the χ2 test. An analysis of clinical symptoms and con-
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sequences of stroke according to the genotype (car-
rier-state of G or C allele) was also performed using
the χ2 test. We analyzed stroke symptoms such as
hemiparesis, hemiplegia, facial nerve paresis, impaired
consciousness, aphasia, headache, and seizures. Dur-
ing the follow-up examination, hemiparesis, worsen-
ing of intellectual function, post-stroke epilepsy, and
aphasia were analyzed. The EpiInfo 6 (WHO) software
was used in all statistical analyses.
Results
General characteristics
At the time of diagnosis, the predominant clinical
symptoms were hemiparesis (60/80 patients) and cen-
tral facial nerve paresis (61 children). Impaired con-
sciousness was observed in 45 patients, aphasia oc -
curred in 41, headaches in 40 and seizures in 14 children
with stroke. The rarest symptom was hemiplegia. 
During the follow-up examination most commonly
reported symptoms were hemiparesis, usually middle-
or low-grade (47 patients), worsening of the intellec-
tual function in 22 patients, post-stroke epilepsy in 
12 children, and aphasia in 7 children. Other symptoms
were observed in 16 patients. The features of the
extrapyramidal syndrome were most common. Using
the classification of ischemic stroke types, most
patients presented partial anterior circulation infarct
(PACI), lacunar infarct (LACI) or total anterior circula-
tion infarct (TACI), only 11 children had posterior cir-
culation infarction (POCI) [2,20]. 
Genotype analysis
The genotype frequencies were in consistence with
the Hardy-Weinberg equilibrium in patients and the
control group.
There were 61 full families (both parents and a child)
analyzed in the transmission/disequilibrium test.
Forty six of them were informative trios (“informative
trio” is a family with at least one heterozygous parent).
Only in such informative families, it was possible to
deduce which allele had been transmitted from the par-
ent to a child. Although the C allele was observed to
be more often transmitted, the difference was not sta-
tistically significant (Table I).
In the case-control model, we also did not observe
any statistical differences in distribution of genotypes
and alleles. There was only a tendency to a higher
prevalence of C allele and CC homozygotes in the chil-
dren with stroke (Table II). The frequency of genotypes
and alleles did not differ between girls and boys. 
The analysis of clinical symptoms and outcome of
stroke showed that only post-stroke epilepsy was geno-
type-dependent. All the children with epilepsy were G
allele carriers and none of them was a CC homozygote,
while about 25% of the children without epilepsy had
the CC genotype (χ2 = 4.01, P = 0.045) (Table III). 
Discussion
In the present study we did not observe any as so-
ciation between the –174G>C polymorphism and stroke
occurrence in children although the frequency of CC
Allele Transmitted Not transmitted χ2; P
G 27 36 0.75; 0.37
C 36 27 0.75; 0.37
Table I. The results of transmission/disequilibri-
um test
Genotype/allele Stroke children Control children 
n % n %
GG 21 26.2 40 29
GC 43 53.8 76 55.1
CC 16 20.0 22 15.9
G 85 53.1 156 56.5
C 75 46.9 120 43.5
GG/GC + CC* χ2 = 0.19, P = 0.66
GG + GC/CC* χ2 = 0.58, P = 0.45
G/C* χ2 = 0.42, P = 0.49
Table II. Distribution of genotypes and alleles 
of the IL-6 gene
*Comparison of stroke children with the control group
Epilepsy** GG + GC CC
0 46 15
1 13* 0
Table III. The analysis of association between
genotype and epilepsy 
*χ2 = 4.01, P = 0.045
**Data available for 74 patients
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homozygotes was slightly higher in patients than in
control children. The transmission of C alleles from par-
ents to the affected children was also slightly more fre-
quent than G alleles, but similarly the difference was
not statistically significant. Applying both methods
allowed to obtain more reliable and informative
results and to avoid some problems often encountered
when applying the case-control design, e.g. the pro per
control group selection. The research of Turkish chil-
dren with stroke gave similar findings although the
authors conducted only a case-control study [15]. 
The comparison of both studies showed that the allele
frequencies significantly differ between the populations
among both patients (46.9% vs. 20.5% for C allele) and
control subjects (43.5% vs. 23.3% for C allele). Such eth-
nic differentiation of allele frequencies seems to make
reasonable association studies even if the relationship
between the specific polymorphism and the disease
was not confirmed in one of the populations. 
Acute inflammation plays a key role in secondary
brain injury induced by ischaemia [13]. Therefore, we
have also analyzed a possible association between the
IL-6 –174G>C polymorphism and some clinical symp-
toms and outcome of stroke in our patients. The analy-
sis showed that only post-stroke epilepsy was geno-
type-dependent. All children with epilepsy were G allele
carriers and none of them was a CC homozygote. The
animal studies showed that the IL-6 level may be relat-
ed to epilepsy. Pro-convulsive effect of recombinant
human interleukin-6 was observed in rats. Transgenic
mice, whose astrocytes produced higher amounts of
IL-6, were characterized by a high susceptibility to
seizures induced by even small doses of kainic acid [1].
Accumulating clinical evidence also strongly supports
the relevance of inflammation in the pathophysiolo-
gy of human epilepsy. The central nervous system (CNS)
injuries such as stroke are considered common risk fac-
tors for developing epilepsy, and long-lasting CNS
inflammation develops rapidly after such events.
Moreover, astrocytic overexpression of cytokines such
as TNF-α or IL-6 results in age-dependent development
of neurological dysfunctions, including seizure sus-
ceptibility and spontaneous seizures. An antiepileptic
activity of selected anti-inflammatory drugs also sug-
gests a role of inflammation in the pathophysiology of
epilepsy [21].
A possible role of the IL-6 polymorphism in the de -
velopment of post-stroke epilepsy may result from its
influence on the IL-6 plasma level. The first report of
Fishman et al. [11] revealed that IL-6 level was nearly
twice as high in subjects with the GG genotype as in
those with the CC genotype. However, subsequent stud-
ies reported conflicting results [23]. Some authors sug-
gest that the genetic control of the IL-6 production is
age and gender dependent. Kilpinen et al. [16] showed
that neonates with the CC genotype secreted signif-
icantly more IL-6 than carriers of the G allele, while the
production of IL-6 in adult controls was not associat-
ed with the IL-6 -174 G>C polymorphism. 
Concluding, our study did not show any associations
between the IL-6 -174 G>C polymorphism and an occur-
rence of stroke, however, we observed a relation of post-
stroke epilepsy with the G allele carrier-state. Yet the
finding should be confirmed in a larger group of
patients.
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